Alphatec Holdings, Inc. (NASDAQ:ATEC) has been given an average broker rating score of 1.67 (Buy) from the three brokers that provide coverage for the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a hold recommendation and two have given a strong buy recommendation to the company. Alphatec’s rating score has improved by 16.5% in the last 90 days as a result of a number of analysts’ upgrades and downgrades.
Brokerages have set a 12-month consensus target price of $4.33 for the company and are predicting that the company will post ($0.21) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Alphatec an industry rank of 112 out of 265 based on the ratings given to its competitors.
Several equities research analysts recently commented on the stock. ValuEngine cut shares of Alphatec from a “sell” rating to a “strong sell” rating in a research report on Friday, December 1st. HC Wainwright reiterated a “buy” rating and issued a $4.00 price target on shares of Alphatec in a research note on Wednesday, November 22nd. Finally, Lake Street Capital started coverage on shares of Alphatec in a research report on Monday, October 16th. They set a “buy” rating and a $7.00 price target on the stock.
Shares of Alphatec (NASDAQ:ATEC) traded up $0.05 during mid-day trading on Tuesday, hitting $2.66. 110,687 shares of the stock traded hands, compared to its average volume of 100,449. Alphatec has a one year low of $1.58 and a one year high of $5.80. The firm has a market cap of $44.82, a price-to-earnings ratio of -1.62 and a beta of 1.35. The company has a quick ratio of 1.08, a current ratio of 2.11 and a debt-to-equity ratio of -1.11.
Large investors have recently modified their holdings of the stock. Fondren Management LP lifted its stake in Alphatec by 20.8% in the 2nd quarter. Fondren Management LP now owns 220,534 shares of the medical technology company’s stock valued at $408,000 after purchasing an additional 37,933 shares during the last quarter. Sabby Management LLC bought a new position in Alphatec in the 2nd quarter valued at approximately $629,000. Finally, Broadfin Capital LLC lifted its stake in Alphatec by 163.1% in the 2nd quarter. Broadfin Capital LLC now owns 594,533 shares of the medical technology company’s stock valued at $1,100,000 after purchasing an additional 368,527 shares during the last quarter. 15.70% of the stock is owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION WARNING: This article was first published by Transcript Daily and is owned by of Transcript Daily. If you are reading this article on another publication, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The legal version of this article can be viewed at https://transcriptdaily.com/2017/12/30/zacks-alphatec-holdings-inc-atec-receives-average-recommendation-of-buy-from-analysts.html.
Alphatec Company Profile
Alphatec Holdings, Inc is a medical technology company. The Company through its subsidiary, Alphatec Spine, Inc and its subsidiaries, designs, develops, manufactures and markets products for the surgical treatment of spine disorders. Its product portfolio and pipeline addresses the cervical, thoracolumbar and intervertebral regions of the spine and covers a range of spinal disorders and surgical procedures.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Alphatec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alphatec and related companies with MarketBeat.com's FREE daily email newsletter.